Primecap Management Co. CA Buys New Stake in Stryker Corporation $SYK

Posted by Brenda Bartman on Aug 26th, 2026

Primecap Management Co. CA purchased a new stake in Stryker Corporation (NYSE:SYK – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 677,872 shares of the medical technology company’s stock, valued at approximately $213,421,000.

Other institutional investors have also modified their holdings of the company. Varma Mutual Pension Insurance Co boosted its holdings in Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after buying an additional 5,100 shares in the last quarter. QRG Capital Management Inc. increased its holdings in Stryker by 7.4% in the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after buying an additional 4,186 shares in the last quarter. Swedbank AB raised its position in shares of Stryker by 6.6% in the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after acquiring an additional 7,934 shares during the period. Royal Bank of Canada raised its position in shares of Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after acquiring an additional 199,863 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its stake in shares of Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after acquiring an additional 6,367 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 355,370 shares of company stock worth $119,447,201. Insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of analyst reports. JPMorgan Chase & Co. dropped their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Leerink Partners lowered their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Truist Financial raised their price objective on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. Finally, Evercore set a $350.00 price objective on Stryker in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Get Our Latest Stock Analysis on Stryker

Stryker Trading Up 1.0%

Shares of SYK stock opened at $331.06 on Wednesday. The stock’s fifty day moving average is $327.80 and its two-hundred day moving average is $331.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm has a market capitalization of $126.98 billion, a P/E ratio of 34.31, a PEG ratio of 2.09 and a beta of 0.76. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86.

Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

About Stryker

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.